The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Oncol.
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1498253
Exfoliative Esophagitis Secondary to Tislelizumab: A Case Report
Provisionally accepted- Lu 'an Hospital of Traditional Chinese Medicine Affiliated to Anhui University of Traditional Chinese Medicine, Lu'an, Anhui Province, China
Tislelizumab, as a PD-1 inhibitor, has demonstrated significant efficacy in cancer treatment. Howe ver, it may also induce immune-related adverse events (irAEs). This case report describes a patient who developed oral ulcers and dysphagia following treatment with tislelizumab, which was diagn osed as exfoliative esophagitis through endoscopic examination. The condition improved after cort icosteroid pulse therapy. A review of the relevant literature revealed no prior reports of immune ch eckpoint inhibitor (ICI)-related esophagitis cases, prompting an exploration of the potential pathop hysiological mechanisms and therapeutic strategies. This report emphasizes the importance of vigi lance for rare irAEs during ICI therapy, advocating for early detection and timely intervention.
Keywords: tislelizumab, exfoliative esophagitis, immune checkpoint inhibitors, Immune-related adverse events, case report
Received: 18 Sep 2024; Accepted: 11 Nov 2024.
Copyright: © 2024 Wang, Sun and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wanhui Dong, Lu 'an Hospital of Traditional Chinese Medicine Affiliated to Anhui University of Traditional Chinese Medicine, Lu'an, Anhui Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.